Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,803 | 341 | 1,431 |
| Samples | 1,478 | 267 | 1,188 |
| Peptides | 1,205 | 195 | 1,040 |
Function
DOCK2 · Dedicator of cytokinesis 2
The protein encoded by this gene belongs to the CDM protein family. It is specifically expressed in hematopoietic cells and is predominantly expressed in peripheral blood leukocytes. The protein is involved in remodeling of the actin cytoskeleton required for lymphocyte migration in response to chemokine signaling. It activates members of the Rho family of GTPases, for example RAC1 and RAC2, by acting as a guanine nucleotide exchange factor (GEF) to exchange bound GDP for free GTP. Mutations in this gene result in immunodeficiency 40 (IMD40), a combined form of immunodeficiency that affects T cell number and function, also with variable defects in B cell and NK cell function. [provided by RefSeq, May 2018].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000520908 | Q92608 | 1,803 | 1,205 |
Gene Properties
Recurrent Mutations
All 1205 amino-acid changes on canonical ENST00000520908 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DOCK2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DOCK2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 7/54 13% | 0/0 0% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Melanoma | 24/210 11% | 165/1899 9% |
| Endometrial Carcinoma | 7/42 17% | 48/612 8% |
| Non-Small Cell Lung Carcinoma | 42/304 14% | 98/1390 7% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 53/810 7% |
| Colorectal Carcinoma | 38/143 27% | 166/3239 5% |
| Gastric Carcinoma | 5/74 7% | 105/1809 6% |
| Other Solid Cancers | 4/94 4% | 79/1515 5% |
| Hepatocellular Carcinoma | 3/46 7% | 93/2210 4% |
| Neuroendocrine Tumour | 18/154 12% | 13/577 2% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Burkitts Lymphoma | 3/32 9% | 6/196 3% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 27/769 4% |
| Biliary Tract Carcinoma | 5/54 9% | 26/950 3% |
| Bladder Carcinoma | 6/58 10% | 24/956 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 21/752 3% |
| Other Sarcomas | 5/69 7% | 15/699 2% |
| Head and Neck Carcinoma | 3/85 4% | 36/1574 2% |
| Germ Cell Tumour | 1/25 4% | 3/169 2% |
| Ovarian Carcinoma | 8/109 7% | 14/998 1% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
| Kidney Carcinoma | 6/85 7% | 24/1862 1% |
| Cervical Carcinoma | 2/35 6% | 5/422 1% |
| Pancreatic Carcinoma | 3/89 3% | 23/1611 1% |
| Non-Cancerous | 0/104 0% | 14/830 2% |
| Rhabdomyosarcoma | 2/33 6% | 1/171 1% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
Mutation Distribution
Where DOCK2 is mutated · all tissues, split by cell line vs tissue
How many mutations in DOCK2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,803 mutations in DOCK2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|